Email Alert | RSS    帮助

中国防痨杂志 ›› 2007, Vol. 29 ›› Issue (5): 382-385.

• 论著 • 上一篇    下一篇

结核分枝杆菌Ag85A/ESAT-6嵌合型质粒DNA疫苗和抗结核药物联合治疗小鼠耐药结核病的效果研究

梁艳;吴雪琼;张俊仙;阳幼荣;王兰;李洪敏;李忠明;史迎昌;   

  1. 中国人民解放军总医院第二附属医院结核病研究所 北京 100091
  • 出版日期:2007-05-10 发布日期:2007-11-03
  • 基金资助:
    WHO基金资助项目(V25-181-202);;中国人民解放军总医院创新基金资助项目

Therapeutic effects of chimeric Ag85A/ESAT-6 DNA vaccines combined with chemotherapy in a mouse model infected with multi-drug resistant Mycobacterium tuberculosis

Liang Yan,Wu Xueqiong,Zhang Junxian,et al.   

  1. Tuberculosis Research Institute,The Second Affiliated Hospital of Chinese PLA General Hospital,Beijing 100091,China
  • Online:2007-05-10 Published:2007-11-03

摘要: 目的研究结核分枝杆菌Ag85A/ESAT-6嵌合型质粒DNA疫苗和抗结核药物联合治疗小鼠耐药结核病的效果。方法用结核分枝杆菌高耐利福平低耐异烟肼临床分离株HB240尾静脉注射BALB/c小鼠1个月后,将小鼠随机分成2组,第1组用利福平(RFP)、异烟肼(INH)治疗12周,第2组用RFP、INH和结核分枝杆菌Ag85A/ESAT-6嵌合型质粒DNA疫苗(免疫5次)联合治疗12周;治疗结束后4和8周,分别取肺、肝和脾观察病理改变、称取质量、作菌落计数。结果治疗结束后4和8周,第2组小鼠体质量均超过第1组,但无显著性差异(P>0.05)。治疗结束后4周,第2组肺、脾脏指数(0.017,0.011)均略低于第1组(0.020,0.012)(P>0.05);治疗结束后8周,第2组肺、肝脏指数(0.021,0.047)均略低于第1组(0.022,0.048)(P>0.05);而第2组脾脏指数(0.008)显著低于第1组(0.012)(P<0.05)。治疗结束后4周,第2组有4例脾脏未见明显病变,第1组仅1例脾脏未见明显病变;治疗结束后8周,第2组有1例肺门淋巴结肿大,而第1组有3例;第2组有5例脾脏未见明显病变,第1组仅2例脾脏未见明显病变。治疗结束后4周,第2组肺菌落计数和脾菌落计数比第1组显著减少,分别减少70%和80%。结论DNA疫苗和抗结核药物联合治疗小鼠耐药结核病疗效高于单纯化疗。

关键词: DNA疫苗, 分枝杆菌,结核

Abstract: Objective To study the therapeutic effects of chimeric Ag85A/ESAT-6 DNA vaccines combined with chemotherapy in a mouse model infected with multi-drug resistant(MDR) Mycobacterium tuberculosis. Methods BALB/c mice were infected by intravenous injection in a tail vein with Mycobacterium tuberculosis clinical isolate HB240 that is resistant to Isoniazid(INH) and Rifampin(RFP) for 4 weeks,and then were randomly divided into tow groups.The mice in group 1 were treated with RFP and INH for 12 weeks.The mice in group 2 were treated by chimeric Ag85A/ESAT-6 DNA vaccines combined with INH and RFP for 12 weeks.DNA vaccines were injected intramuscularly 5 times at 3 weeks intervals.The lungs,livers and spleens were taken and observed their pathological changes,weighted and performed mycobacteria cultures at 4 or 8 weeks after terminative treatment. Results At four and eight weeks after terminative treatment,the body weights of mice in group 2 were lower than that in group 1,but it had no significant difference(P>0.05).At four weeks after terminative treatment,indexes of the lungs and spleens(0.017,0.011)from the mice in group 2 were lower than that in group 1 (0.020,0.012).No swell of spleen could be observed in 1 mouse from group 2 and 4 mice from group 1.The numbers of bacteria in the lungs and spleens from mice in group 2 decreased 2.5 times and 4 times than those in group 1,respectively.At eight weeks after terminative treatment,indexes of the lungs and livers from the mice in group 2(0.021,0.047)were lower than that in group 1(0.022,0.048)(P>0.05),but indexes of the spleens from the mice in group 2(0.008)were significantly lower than that in group 1(0.012)(P<0.05).The swell of the lymph node of lung could be observed in 1 mouse from group 2 and 3 mice from group 1,no swell of spleen could be observed in 5 mice from group 2 and 2 mice from group 1. Conclusion The therapeutic efficacy of DNA vaccine combined with chemotherapy is stronger significantly than that of chemotherapy alone in the mouse model of MDR-tuberculosis.

Key words: DNA vaccine, Multi-drug resistance, Mycobacterium tuberculosis